VUNO has signed its first Middle East export agreement for its AI-powered portable ECG device, HATIV P30, through an exclusive distribution partnership with Egypt-based Health Arena. The agreement covers Egypt, the UAE, Saudi Arabia, Kuwait, and Iraq, marking a major step in the company’s global expansion.

The partnership follows VUNO’s participation at CardioAlex, one of the largest cardiology conferences in the Middle East and Africa, where the company showcased the six-lead portable ECG device. HATIV P30 has received regulatory approvals in Europe, the UK, Egypt, and Indonesia, supporting its international rollout.

The company said “rising demand for digital health and telemedicine solutions across the Middle East presents significant opportunities for AI-enabled cardiac diagnostics. Through its local partnership, VUNO aims to improve access to fast and accurate ECG testing across the region.”

Click here to join our WhatsApp channel here

VUNO CEO Lee Ye-ha stated, “Through participating in these overseas medical events, we confirmed the high local interest in VUNO’s solutions. Based on our first export result in the Middle East, we will accelerate our entry into the global market by leveraging our proven product competitiveness and local partnerships.”

Also read: WHO Releases New Blueprint to Combat Fungal Diseases and Antifungal Resistance

Alongside its Middle East expansion, VUNO also participated in the Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) 2026 in Thailand, where it showcased its VUNO Med-Fundus AI solution. The company plans to further expand its ophthalmology AI portfolio across Southeast Asia, Europe, and the Middle East.